Latest Articles
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? Medpage Today
Published: Feb. 5, 2025, 7:31 p.m.
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive
Published: Feb. 5, 2025, 5:17 p.m.
The Link Between Cancer and Endometriosis You Need to Know About - Well+Good
The Link Between Cancer and Endometriosis You Need to Know About Well+Good
Published: Feb. 5, 2025, 3:33 p.m.
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting - Cureus
A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting Cureus
Published: Feb. 5, 2025, 1:26 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status StockTitan
Published: Feb. 5, 2025, 1 p.m.
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron - Nature.com
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron Nature.com
Published: Feb. 5, 2025, 11:37 a.m.
Cancer risk could increase by hot water bottle use, doctor warns - Gloucestershire Live
Cancer risk could increase by hot water bottle use, doctor warns Gloucestershire Live
Published: Feb. 4, 2025, 1:40 p.m.
Link copied to clipboard!